Treating donor tissue with a special cocktail of molecules improves outcomes and promotes survival of high-risk corneal transplants

Boston, Mass. — Treating donor corneas with a cocktail of molecules prior to transplanting to a host may improve survival of grafts and, thus, outcomes in high-risk corneal transplant patients, according to a new study led by researchers at Massachusetts Eye and Ear. The findings, 

Regulating transcription factor RUNX1 using small molecule drugs a promising novel therapy for diseases of the retina, including advanced diabetic eye disease.

Fundus photograph of the left eye in a patient with proliferative diabetic

From May 1^st to May 5^th, more than 11,000 people attended the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting in Seattle, WA. Eye and vision researchers from more than 75 countries presented their current research, discussed emerging technologies, and strategized ways to overcome the current challenges facing ophthalmology and vision science. Harvard Ophthalmology was well-represented at the meeting, and faculty and trainees contributed 247 posters and presentations this year.

ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, has announced that Joan W. Miller, MD, Chair of the Department of Ophthalmology, Harvard Medical School and Chief of Ophthalmology at Massachusetts Eye and Ear and Massachusetts General Hospital, is one of five of the world’s premier retinal disease thought leaders who will serve on its newly formed scientific advisory board (SAB). The goal of